Hologic Reports Q3 Earnings: EPS Beats Expectations, Revenue Tops Estimates

Hologic reported Q3 non-GAAP EPS of $1.08, beating expectations by $0.03. Revenue was $1.02B, up 1.2% for the quarter and 0.4% in constant currency, exceeding forecasts by $10M. Shares rose 0.08%. The company provided guidance for Q4 and full-year 2025, including non-GAAP EPS and revenue targets.

Hologic, Inc. (HOLX) announced its financial results for the third quarter of fiscal 2025, which ended June 28, 2025. The company reported non-GAAP diluted EPS of $1.08, exceeding analysts' expectations by $0.03. Revenue reached $1.02 billion, up 1.2% for the quarter and 0.4% in constant currency, surpassing forecasts by $10 million. Shares of HOLX rose by 0.08% following the announcement.

Key highlights from the quarter include:
- Revenue: $1.02 billion, up 1.2% year-over-year, and 0.4% in constant currency.
- Non-GAAP EPS: $1.08, up 1.9% year-over-year, beating the high-end of guidance.
- Diagnostics Revenue: $448.9 million, up 1.8% year-over-year.
- Molecular Diagnostics Revenue: $320.5 million, up 3.2% year-over-year.
- Breast Health Revenue: $365.2 million, down 5.1% year-over-year.
- Surgical Revenue: $178.4 million, up 7.1% year-over-year.

The company also provided guidance for the fourth quarter and full-year 2025, including non-GAAP EPS and revenue targets.

References:
[1] https://www.nasdaq.com/articles/seeking-clues-hologic-holx-q3-earnings-peek-wall-street-projections-key-metrics
[2] https://www.stocktitan.net/news/HOLX/hologic-announces-financial-results-for-third-quarter-of-fiscal-6qk9w6afeix8.html